MedTrace Logo

Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine

NCT04946734 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2025-03-12

No results posted yet for this study

Summary

Effectivity and safety of PFO closure vs medicine in alleviating migraine （SPRING）: a multicenter, random, case control study

Conditions

Interventions

DEVICE

PFO closure device

Device PFO closure.

DRUG

Aspirin and clopidogrel

Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.

DRUG

Triptans

If migraine recurred, Triptans would be administered during the acute phase.

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-12
Primary Completion
2025-09-06
Completion
2025-09-06

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04946734 on ClinicalTrials.gov